Immunotherapy-Chemo cocktail targets Hard-to-Treat MDS
NCT ID NCT02530463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus a chemotherapy drug (azacitidine) in 99 people with myelodysplastic syndromes (MDS), a type of blood cancer. The goal is to see if the combination improves response rates, especially in patients who have not responded to standard treatments. Participants receive the drugs intravenously, and the study tracks side effects and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab, ipilimumab, and azacitidine
- What this could lead to
- If it works, this could offer a new treatment option for people with myelodysplastic syndromes, especially those who have not responded to standard therapy.
- What could go wrong
- This is an early phase 2 trial with only 99 participants, so results may not apply to everyone. The combination of drugs can cause serious side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells stop blood cancer relapse?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can donor immune cells tame stem cell transplant risks?
- A guided path back to work after blood cancer: a trial tests the impact